Keyword: Kymriah (tisagenlecleucel)
Novartis is blazing ahead with its bid to take its CAR-T therapy Kymriah into new realms with a double-pronged application in Europe.
Cutting-edge cell therapies from Novartis and Gilead aren't direct rivals for now, but with a new FDA filing, that could change—and soon.
Novartis investors were disappointed when CEO Joe Jimenez said that a decision about eye unit Alcon would be delayed.
Kite's new CAR-T approval vaults it and new parent Gilead into a market first launched by Novartis—and into the debate over high drug prices.
Novartis is only in the very early days of its Kymriah rollout in the U.S., but company executives aren't only focusing on the States.
Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.
Vas Narasimhan will take over as CEO of Novartis in February 2018 and will be inheriting several challenges, not the least of which is pricing pressure on both branded and generic drugs.
Novartis nabbed its anticipated FDA nod for CAR-T treatment tisagenlecleucel, a first-ever cell therapy, to be marketed as Kymriah.